COMMUNIQUÉS West-GlobeNewswire

CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ la société pharmaceutique de [...]
Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT
04/02/2026
Communiqué de Presse Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT Dijon, le 04 février 2026 Au titre du contrat de liquidité confié par la société CROSSJECT à Rothschild [...]
Glow Holdings, Inc. Provides Corporate Update Following GlohCo Introduction and Initial Industry Engagement
04/02/2026
HOUSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, today provided a corporate update following the recent introduction of its GlohCo health intelligence platform and [...]
Lightship Inc. Acquires Veda Trials to Expand Community-Based Clinical Research Delivery
04/02/2026
The acquisition expands scalable trial operations across real-world care settings RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Lightship Inc. , the modern clinical trial site organization committed to [...]
INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth
04/02/2026
SARASOTA, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility [...]
HealthEdge Awarded ‘Best in KLAS’ Designation for Pre-Payment Integrity
04/02/2026
HealthEdge Source™ Ranks Highest Overall in Pre-Payment Accuracy & Integrity Market and is the Only Solution to Increase its Score Year Over Year, According to Customer Assessments BOSTON, Feb. 04, 2026 (GLOBE [...]
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
04/02/2026
Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it [...]
PerfectServe is Again Best in KLAS for Physician Scheduling and Ambulatory Clinical Communications
04/02/2026
Awards reinforce company’s decades-long mission to deliver measurable outcomes in scheduling and care coordination for healthcare organizations MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a leading [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
Novo Nordisk files annual report with the SEC
04/02/2026
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of [...]
H1 Named to the 2026 DHNY Hall of Fame After Five Years of Recognition
04/02/2026
Honoring the companies that helped build the foundation of New York's digital health ecosystem NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- H1 , on a mission to connect the world with the right doctors, today announced [...]
Branded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of Shares
04/02/2026
Company has decisively eliminated $1,078,500 in legacy convertible debt VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG ), today announced that Interim Chief [...]
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
04/02/2026
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]
SAFE - Croissance de 6,5 % du chiffre d’affaires 2025 - Confirmation de la feuille de route
04/02/2026
Croissance de 6,5 % du chiffre d’affaires 2025 Confirmation de la feuille de route Fleurieux-sur-l’Arbresle - France - le 4 février 2026 à 18h. Safe Group publie son chiffre d’affaires annuel consolidé pour l'exercice [...]
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
04/02/2026
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDA Clinical entry validates condensate modulator discovery platform and its potential to [...]
CROSSJECT - NOVEMBRE 2026 : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
04/02/2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – [...]
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
04/02/2026
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong [...]
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
04/02/2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]

Pages